Clene Inc. logo

Clene Inc.(CLNN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$3.92
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CLNN

11/13/2026: CLNN (1-star) is currently NOT-A-BUY. Pass it for now.

Clene Inc. is a clinical-stage biopharmaceutical company that develops clean-surfaced nanotechnology therapeutics for neurodegenerative diseases. The company's primary strength lies in its innovative nanocrystal platform and lead drug candidate, CNM-Au8, which targets conditions like ALS and multiple sclerosis. Its main investment appeal centers on potential regulatory approvals and clinical milestones that could validate its platform. However, the company faces substantial risks, including minimal commercial revenue, ongoing net losses, high cash burn, and binary regulatory outcomes. Clene is best suited for speculative growth or momentum investors comfortable with high volatility, while market participants should closely monitor FDA regulatory updates and capital-raising activities.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitClene lacks consistent revenue growth and relies entirely on clinical-stage pipeline catalysts.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp, catalyst-driven price spikes around clinical data readouts and regulatory updates.
Value investorWeak fitThe company generates minimal revenue and ongoing net losses, making traditional fundamental value metrics inapplicable.
Dividend investorWeak fitClene does not pay dividends and reinvests all capital into clinical development.
Low-risk investorWeak fitHigh clinical trial risks, financing dilution, and price volatility make the stock unsuitable for conservative strategies.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is highly sensitive to regulatory news, clinical trial outcomes, and financing announcements.
Valuation riskHighPricing is driven heavily by binary clinical and regulatory expectations rather than current earnings.
Competition risk (neurodegenerative drug development)Medium / highThe company faces intense competition from well-funded biotech firms pursuing alternative ALS and MS therapies.
Business qualityMediumClene possesses an innovative proprietary technology platform, but lacks commercial scale or stable profitability.
Dividend incomeLow / noneNo dividend is paid or anticipated in the foreseeable future.
Execution riskHighSuccess depends entirely on navigating complex FDA regulatory pathways and securing sufficient ongoing funding.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 56.45M USD
Price to earnings Ratio -
1Y Target Price 32.2
Price to earnings Ratio -
1Y Target Price 32.2
Volume (30-day avg) 96.3K shares
Beta 1.06
52 Weeks Range 3.02 - 10.84
Updated Date 11/15/2026
52 Weeks Range 3.02 - 10.84
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.3

Sector & Industry Intelligence

Sector

Consumer Defensive

Defensive
Sentiment
Correction Expected
Momentum
BUY Breadth Improving
BUY participation
95.0%
Active BUY / eligible
19 / 20
30-Day BUY Count Change
+13
Market state
Correction Expected

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Industry classification is unavailable for this snapshot.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -54.58%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CLNN receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CLNN has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+33.6%) is partially offset by weak cash generation (FCF margin -9292.5%), negative revenue growth (-41.5%), weak profitability (net margin -13086.5%).

Financial Health Rating

★★★★★
CLNN's financial health is soft, with the relatively strongest area being moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 11620.0% of revenue). Liquidity is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is CLNN's strongest growth driver at +33.6% FY2025 versus FY2024 (solid, 4 stars). By comparison, free-cash-flow growth (+12.9%, solid) is also solid, while revenue growth (-41.5%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 20.2% and approximately 82.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 16.35% supports management-shareholder alignment.

Unit Economics (Per $1K Revenue)

★★★★★
CLNN generates approximately $785 of gross profit, $-115,415 of operating income, and $-92,925 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
CLNN has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Small / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Dietary SupplementsCommercial sales of wellness supplement products utilizing nanocrystal formulations through partner distribution channels.Supplement sales provide nominal sideline revenue, but the company's core economic value depends on future drug approvals.
Clinical Therapeutics (Pipeline)Future potential commercialization, milestone payments, and licensing revenues from drug candidates like CNM-Au8.Substantially all future enterprise value rests on the clinical success and regulatory approval of its proprietary neurodegenerative treatments.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-11-04
When Before Market
Estimate -0.46
Actual 0.05

Profitability

Profit Margin -
Operating Margin (TTM) -8928.57%

Management Effectiveness

Return on Assets (TTM) -59.73%
Return on Equity (TTM) -1738.36%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 69.89M
Price to Sales(TTM) 237.18
Enterprise Value 69.89M
Price to Sales(TTM) 237.18
Enterprise Value to Revenue 293.64
Enterprise Value to EBITDA -1.13
Shares Outstanding 14.40M
Shares Floating 11.84M
Shares Outstanding 14.40M
Shares Floating 11.84M
Percent Insiders 16.35
Percent Institutions 20.17

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.